Selahittin Çayan1, Mustafa Uğuz2, Barış Saylam3, Erdem Akbay1. 1. Department of Urology, University of Mersin School of Medicine, Mersin, Turkey. 2. Department of Infectious diseases, Mersin City Educational and Research Hospital, Mersin, Turkey. 3. Department of Urology, Mersin City Educational and Research Hospital, Mersin, Turkey.
Abstract
OBJECTIVE: To investigate effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected male patients. METHODS: This prospective cohort study included 221 consecutive male patients (>18 years old) with laboratory confirmed SARS-CoV-2 who had been hospitalized due to COVID-19. The patients were divided into 3 groups: Asymptomatic patients (n: 46), symptomatic patients who were hospitalized in the internal medicine unit (IMU) (n: 129), and patients who were hospitalized in the intensive care unit (ICU) (n: 46). RESULTS: As serum total testosterone level at baseline decreases, probability (%) to be in the ICU significantly increases (p = 0.001). As serum total testosterone level at baseline decreases, probability (%) of mortality significantly increases (p = 0.002). In the patients who had pre-COVID-19 serum gonadal hormones test (n: 24), serum total testosterone level significantly decreased from pre-COVID-19 level of 458 ± 198 ng/dl to 315 ± 120 ng/dl at the time of COVID-19 in the patients (p = 0.003). CONCLUSIONS: COVID-19 might deteriorate serum testosterone level in SARS-CoV-2 infected male patients. Low serum total testosterone level at baseline has a significant increased risk for the ICU and mortality in patients with COVID-19.
OBJECTIVE: To investigate effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected male patients. METHODS: This prospective cohort study included 221 consecutive male patients (>18 years old) with laboratory confirmed SARS-CoV-2 who had been hospitalized due to COVID-19. The patients were divided into 3 groups: Asymptomatic patients (n: 46), symptomatic patients who were hospitalized in the internal medicine unit (IMU) (n: 129), and patients who were hospitalized in the intensive care unit (ICU) (n: 46). RESULTS: As serum total testosterone level at baseline decreases, probability (%) to be in the ICU significantly increases (p = 0.001). As serum total testosterone level at baseline decreases, probability (%) of mortality significantly increases (p = 0.002). In the patients who had pre-COVID-19 serum gonadal hormones test (n: 24), serum total testosterone level significantly decreased from pre-COVID-19 level of 458 ± 198 ng/dl to 315 ± 120 ng/dl at the time of COVID-19 in the patients (p = 0.003). CONCLUSIONS: COVID-19 might deteriorate serum testosterone level in SARS-CoV-2 infected male patients. Low serum total testosterone level at baseline has a significant increased risk for the ICU and mortality in patients with COVID-19.
Authors: Sandeep Dhindsa; Nan Zhang; Michael J McPhaul; Zengru Wu; Amit K Ghoshal; Emma C Erlich; Kartik Mani; Gwendalyn J Randolph; John R Edwards; Philip A Mudd; Abhinav Diwan Journal: JAMA Netw Open Date: 2021-05-03
Authors: G Corona; W Vena; A Pizzocaro; F Pallotti; D Paoli; G Rastrelli; E Baldi; N Cilloni; M Gacci; F Semeraro; A Salonia; S Minhas; R Pivonello; A Sforza; L Vignozzi; A M Isidori; A Lenzi; M Maggi; F Lombardo Journal: J Endocrinol Invest Date: 2022-05-09 Impact factor: 5.467
Authors: Lukas Lanser; Francesco Robert Burkert; Lis Thommes; Alexander Egger; Gregor Hoermann; Susanne Kaser; Germar Michael Pinggera; Markus Anliker; Andrea Griesmacher; Günter Weiss; Rosa Bellmann-Weiler Journal: Front Endocrinol (Lausanne) Date: 2021-06-18 Impact factor: 5.555